"Preclinical studies suggest that this prohealing alternative to the delayed healing seen with DES systems may give way to an entirely new class of stents that combat restenosis while eliminating the risk of late stent thrombosis."

— Mark Bates, MD, Nexeon CEO, discussing the potential for his company Nexeon's new Protex coronary stent which just began a clinical trial enrollment, " Paragon now becomes Nexeon, and gets $24M for Protex study."